Hikma v. Amarin — Supreme Court Protects Skinny-Label Generics from Induced Infringement Claims
A unanimous Supreme Court reversed the Federal Circuit and ended Amarin’s induced infringement suit against Hikma’s skinny-label generic of Vascepa, holding that anodyne marketing references to the branded drug do not plausibly allege that a generic maker actively encouraged infringing u